Olema Pharmaceuticals, Inc.
HealthcareNASDAQ:OLMA · NASDAQ Global Select
+$0.12 today
Vol 1.60M · Avg 1.28M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-33.9%
avg -14.1%
ROIC
-37.0%
avg 10.2%
ROA
-30.5%
avg -438.7%
Analysis
ROA is currently the strongest return metric at -30.5% versus its period average of -438.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Sean Bohen | President, CEO, Interim Principal Financial Officer & Director | $1.18M | — | 59 | $850,000.00 | 0.97% |
Shane William Charles Kovacs | Consultant | $902,735.00 | — | 52 | $139,727.00 | 0.16% |
Naseem Zojwalla | Chief Medical Officer | $777,970.00 | — | 53 | $250,000.00 | 0.29% |
Shawnte Mitchell | Chief Legal Officer & Corporate Secretary | $664,750.00 | — | 48 | $233.00 | <0.01% |
David C. Myles | Chief Scientific Officer | $200,000.00 | — | 63 | $250,000.00 | 0.29% |
Julie Dexter | Senior Vice President & Head of People | — | — | — | — | — |
Meghna Chowdary | Senior Vice President of Commercial Strategy & Operations | — | — | — | — | — |
Sasha Austin | Vice President of Finance & Controller | — | — | — | $29,250.00 | 0.03% |
Angelos Dovletoglou | Senior Vice President of CMC & Supply Chain | — | — | — | — | — |
Kamesh Kuchimanchi | Senior Vice President of Regulatory Affairs & Quality Assurance | — | — | — | — | — |
Mark Shilkrut | Senior Vice President of Clinical Development | — | — | — | $2.91M | 3.33% |
Richard Hernandez | Senior Vice President of Clinical Development Operations | — | — | — | — | — |
Courtney O'Konek | Vice President of Corporate Communications | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
27
$24.65M
Net Sentiment
$24.65M
Net selling
Most Active
Myles David C.
8 transactions
1–10 of 27
Analysis
Insiders reported 0 buys worth $0.00 and 27 sells worth $24.65M over the last 12 months. That adds up to net selling of $24.65M. Myles David C. was the most active insider with 8 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
$1.44B
Absci Corporation
NASDAQ:ABSI
$1.06B
Ventyx Biosciences, Inc.
VTYX
$1.00B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$1.00B
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
$852.86M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$461.60M
Prothena Corporation plc
NASDAQ:PRTA
$431.91M
REGENXBIO Inc.
NASDAQ:RGNX
$344.31M
Verastem, Inc.
NASDAQ:VSTM
$284.19M
Gossamer Bio, Inc.
GOSS
$38.00M
Who manages OLMA?
Olema Pharmaceuticals, Inc. (OLMA) lists 13 active executives. The top listed executive is Julie Dexter, Senior Vice President & Head of People.
Are OLMA insiders buying or selling?
Recent insider activity shows net selling of $139,013.57.
Explore More
Continue the stock analysis
Jump to another research area for this company.